Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in:

Open Access 15-07-2024 | Cushing's Syndrome

Cushing’s disease and bone

Authors: Aleksandra Zdrojowy-Wełna, Barbara Stachowska, Marek Bolanowski

Published in: Pituitary | Issue 6/2024

Login to get access

Abstract

Bone impairment associated with Cushing’s disease (CD) is a complex disorder, mainly involving deterioration of bone quality and resulting in an increased fracture rate, often despite normal bone mineral density. Bone complications are common in patients with CD at the time of diagnosis but may persist even after successful treatment. There is currently no agreement on the optimal diagnostic methods, thresholds for anti-osteoporotic therapy and its timing in CD. In this review, we summarize the current data on the pathophysiology, diagnostic approach and management of bone complications in CD.
Literature
1.
2.
Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9:847–875PubMedPubMedCentralCrossRef
3.
4.
Giuliodori A, Soudah E, Malouf J, Martel-Duguech L, Amodru V, Gil J et al (2024) Evaluation of bone-related mechanical properties in female patients with long-term remission of Cushing’s syndrome using quantitative computed tomography–based finite element analysis. Eur J Endocrinol 190:86–95PubMedCrossRef
5.
6.
Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M et al (2003) Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin Endocrinol (Oxf) 58:302–308PubMedCrossRef
7.
Ohmori N, Nomura K, Ohmori K, Kato Y, Itoh T, Takano K (2003) Osteoporosis is more prevalent in adrenal than in pituitary Cushing’s syndrome. Endocr J 50:1–7PubMedCrossRef
8.
Tauchmanovà L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L et al (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91:1779–1784PubMedCrossRef
9.
Trementino L, Appolloni G, Ceccoli L, Marcelli G, Concettoni C, Boscaro M et al (2014) Bone complications in patients with Cushing’s syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 25:913–921CrossRef
10.
Zhou H, Cooper MS, Seibel MJ (2013) Endogenous Glucocorticoids and Bone Bone Res 1:107–119PubMed
11.
12.
13.
Frara S, di Filippo L, Doga M, Loli P, Casanueva FF, Giustina A (2022) Novel approaches to bone comorbidity in Cushing’s disease: an update. Pituitary 25:754–759PubMedCrossRef
14.
Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res 16:97–103CrossRef
15.
Belaya ZE, Grebennikova TA, Melnichenko GA, Nikitin AG, Solodovnikov AG, Brovkina OI et al (2018) Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 29:211–221CrossRef
16.
van Lierop AH, van der Eerden AW, Hamdy NT, Hermus AR, den Heijer M, Papapoulos SE (2012) Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 97:1953–1957CrossRef
17.
Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M et al (2009) Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 60:1427–1437PubMedCrossRef
18.
19.
Uygur MM, Frara S, di Filippo L, Giustina A (2023) New tools for bone health assessment in secreting pituitary adenomas. Trends Endocrinol Metab TEM 34:231–242PubMedCrossRef
20.
Kim SM, Sultana F, Korkmaz F, Lizneva D, Yuen T, Zaidi M (2022) Independent skeletal actions of pituitary hormones. Endocrinol Metab 37:719–731CrossRef
21.
Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M (2004) Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing’s syndrome. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 15:855–861CrossRef
22.
23.
Martel-Duguech L, Alonso-Jiménez A, Bascuñana H, Díaz-Manera J, Llauger J, Nuñez-Peralta C et al (2020) Thigh muscle fat infiltration is associated with impaired physical performance despite remission in Cushing’s syndrome. J Clin Endocrinol Metab 105:2039–2049CrossRef
24.
Vogel F, Braun LT, Rubinstein G, Zopp S, Künzel H, Strasding F et al (2020) Persisting muscle dysfunction in Cushing’s syndrome despite biochemical remission. J Clin Endocrinol Metab 105(12):e4490–e4498PubMedPubMedCentralCrossRef
25.
Amodru V, Ferriere A, Tabarin A, Castinetti F, Tsagarakis S, Toth M et al (2023) Cushing’s syndrome in the elderly: data from the European Registry on Cushing’s syndrome. Eur J Endocrinol 188(4):395–406PubMedCrossRef
26.
Vogel F, Braun L, Rubinstein G, Zopp S, Benedix S, Schneider H et al (2021) Patients with low IGF-I after curative surgery for Cushing’s syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. Eur J Endocrinol 184:813–821PubMedCrossRef
27.
Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E et al (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54:603–611PubMedCrossRef
28.
Formenti AM, Maffezzoni F, Doga M, Mazziotti G, Giustina A (2017) Growth hormone deficiency in treated acromegaly and active Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 31:79–90PubMedCrossRef
29.
Mazziotti G, Doga M, Frara S, Maffezzoni F, Porcelli T, Cerri L et al (2016) Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52:103–110PubMedCrossRef
30.
Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A (2016) Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol 4:611–629PubMedCrossRef
31.
Johannsson G, Sunnerhagen KS, Svensson J (2004) Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing’s disease. Clin Endocrinol (Oxf) 60:550–559PubMedCrossRef
32.
Scommegna S, Greening JP, Storr HL, Davies KM, Shaw NJ, Monson JP et al (2005) Bone mineral density at diagnosis and following successful treatment of pediatric Cushing’s disease. J Endocrinol Invest 28:231–235PubMedCrossRef
33.
van Varsseveld NC, van Bunderen CC, Franken AM, Koppeschaar HPF, van der Lely AJ, Drent ML (2016) Fractures in pituitary adenoma patients from the Dutch National Registry of growth hormone treatment in adults. Pituitary 19:381–390PubMedPubMedCentralCrossRef
34.
35.
36.
Delucchi Á, Toro L, Alzamora R, Barrientos V, González M, Andaur R et al (2019) Glucocorticoids decrease longitudinal bone growth in pediatric kidney transplant recipients by stimulating the FGF23/FGFR3 signaling pathway. J Bone Miner Res 34:1851–1861PubMedCrossRef
37.
Bonadonna S, Burattin A, Nuzzo M, Bugari G, Rosei EA, Valle D et al (2005) Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 152:199–205PubMedCrossRef
38.
Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M et al (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37:141–148PubMedCrossRef
39.
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633PubMedPubMedCentralCrossRef
40.
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355PubMedCrossRef
41.
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039PubMedCrossRef
42.
43.
44.
Papadakis GE, de Kalbermatten B, Dormoy A, Salenave S, Trabado S, Vieira-Pinto O et al (2023) Impact of Cushing’s syndrome on the gonadotrope axis and testicular functions in men. Hum Reprod Oxf Engl 38:2350–2361CrossRef
45.
Zheng H, Wang Q, Cui Q, Sun Q, Wu W, Ji L et al (2022) The hypothalamic-pituitary-gonad axis in male Cushing’s disease before and after curative surgery. Endocrine 77:357–362PubMedCrossRef
46.
Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888–3921PubMedCrossRef
47.
dos Santos CV, Vieira Neto L, Madeira M, Alves Coelho MC, de Mendonça LMC, Paranhos-Neto FP et al (2015) Bone density and microarchitecture in endogenous hypercortisolism. Clin Endocrinol (Oxf) 83:468–474PubMedCrossRef
48.
Carrone F, Ariano S, Piccini S, Milani D, Mirani M, Balzarini L et al (2021) Update on vertebral fractures in pituitary diseases: from research to clinical practice. Horm Athens Greece 20:423–437CrossRef
49.
Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261PubMedCrossRef
50.
Cianferotti L, Cipriani C, Corbetta S, Corona G, Defeudis G, Lania AG et al (2023) Bone quality in endocrine diseases: determinants and clinical relevance. J Endocrinol Invest 46:1283–1304PubMedCrossRef
51.
Saag KG, Agnusdei D, Hans D, Kohlmeier LA, Krohn KD, Leib ES et al (2016) Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide: trabecular bone score in glucocorticoid-induced osteoporosis. Arthritis Rheumatol 68:2122–2128PubMedCrossRef
52.
53.
Vinolas H, Grouthier V, Mehsen-Cetre N, Boisson A, Winzenrieth R, Schaeverbeke T et al (2018) Assessment of vertebral microarchitecture in overt and mild Cushing’s syndrome using trabecular bone score. Clin Endocrinol (Oxf) 89:148–154PubMedCrossRef
54.
Ferraù F, Giovinazzo S, Alessi Y, Catalano A, Tessitore A, Mormina E et al (2023) Trabecular bone score, bone marrow fat and vertebral fractures in Cushing syndrome. Endocrine 80(2):441–447PubMedCrossRef
55.
Ferraù F, Giovinazzo S, Messina E, Tessitore A, Vinci S, Mazziotti G et al (2020) High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures. Endocrine 67:172–179PubMedCrossRef
56.
Chiodini I, Carnevale V, Torlontano M, Fusilli S, Guglielmi G, Pileri M et al (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in Eumenorrheic patients with Cushing’s syndrome. J Clin Endocrinol Metab 83:1863–1867PubMed
57.
Cheung WH, Hung VWY, Cheuk KY, Chau WW, Tsoi KKF, Wong RMY et al (2020) Best performance parameters of HR-pQCT to predict fragility fracture: systematic review and meta-analysis. J Bone Miner Res 36:2381–2398CrossRef
58.
Guo W, Li F, Zhu C, Wang B, Wang K, Dai C et al (2018) Effect of hypercortisolism on bone mineral density and bone metabolism: a potential protective effect of adrenocorticotropic hormone in patients with Cushing’s disease. J Int Med Res 46:492–503PubMedCrossRef
59.
60.
Cortet B, Cortet C, Blanckaert F, d’Herbomez M, Marchandise X, Wémeau JL et al (2001) Quantitative ultrasound of bone and markers of bone turnover in Cushing’s syndrome. Osteoporos Int 12:117–123PubMedCrossRef
61.
Braun LT, Fazel J, Zopp S, Benedix S, Osswald-Kopp A, Riester A et al (2020) The effect of biochemical remission on bone metabolism in Cushing’s syndrome: a 2-year follow-up study. J Bone Miner Res 35:1711–1717PubMedCrossRef
62.
Vestergaard P, Lindholm J, Jørgensen JOL, Hagen C, Hoeck HC, Laurberg P et al (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146:51–56PubMedCrossRef
63.
Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154:109–118PubMedCrossRef
64.
Papakokkinou E, Olsson DS, Chantzichristos D, Dahlqvist P, Segerstedt E, Olsson T et al (2020) Excess morbidity persists in patients with Cushing’s disease during long-term remission: a Swedish nationwide study. J Clin Endocrinol Metab 105:2616–2624CrossRef
65.
Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M et al (2021) Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev Endocr Metab Disord 22:1201–1218PubMedPubMedCentralCrossRef
66.
67.
68.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) 2017 American College of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521–1537PubMedCrossRef
69.
Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRef
70.
Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Wen A et al (2021) Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatol Oxf Engl 60:649–657CrossRef
71.
Ding L, Hu J, Wang D, Liu Q, Mo Y, Tan X et al (2020) Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures. J Clin Endocrinol Metab 105:600–613CrossRef
72.
Di Somma C, Colao A, Pivonello R, Klain M, Faggiano A, Tripodi FS et al (1998) Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing’s disease. Clin Endocrinol (Oxf) 48:655–662PubMedCrossRef
73.
Scillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R et al (2014) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 25:441–446CrossRef
74.
75.
76.
77.
Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV et al (2013) Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 24:2191–2199CrossRef
78.
Crawford BAL, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176PubMedCrossRef
79.
Hall GM, Daniels M, Doyle DV, Spector TD (1994) Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37:1499–1505PubMedCrossRef
80.
Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK et al (2011) Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70:778–784PubMedCrossRef
Metadata
Title
Cushing’s disease and bone
Authors
Aleksandra Zdrojowy-Wełna
Barbara Stachowska
Marek Bolanowski
Publication date
15-07-2024
Publisher
Springer US
Published in
Pituitary / Issue 6/2024
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-024-01427-7

Other articles of this Issue 6/2024

Acromegaly and COVID-19, lessons, and new opportunities

Pituitary surgery and COVID

Neuroendocrinology of bone

Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19

Hypopituitarism and COVID-19

Vitamin D in pituitary driven osteopathies

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar
Image Credits